| A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. | |
| | |
MedLine Citation:
|
PMID: 22108825 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Little research has been done to address the huge opportunities that may exist to reposition existing approved or generic drugs for alternate uses in cancer therapy. In addition, there has been little work on strategies to reposition experimental cancer agents for testing in alternate settings that could shorten their clinical development time. Progress in each area has lagged, in part, because of the lack of systematic methods to define drug off-target effects (OTE) that might affect important cancer cell signaling pathways. In this study, we addressed this critical gap by developing an OTE-based method to repurpose drugs for cancer therapeutics, based on transcriptional responses made in cells before and after drug treatment. Specifically, we defined a new network component called cancer-signaling bridges (CSB) and integrated it with a Bayesian factor regression model (BFRM) to form a new hybrid method termed CSB-BFRM. Proof-of-concept studies were conducted in breast and prostate cancer cells and in promyelocytic leukemia cells. In each system, CSB-BFRM analysis could accurately predict clinical responses to more than 90% of drugs approved by the U.S. Food and Drug Administration and more than 75% of experimental clinical drugs that were tested. Mechanistic investigation of OTEs for several high-ranking drug-dose pairs suggested repositioning opportunities for cancer therapy, based on the ability to enforce retinoblastoma-dependent repression of important E2F-dependent cell-cycle genes. Together, our findings establish new methods to identify opportunities for drug repositioning or to elucidate the mechanisms of action of repositioned drugs. |
| | |
Authors:
|
Guangxu Jin; Changhe Fu; Hong Zhao; Kemi Cui; Jenny Chang; Stephen T C Wong |
Related Documents
:
|
10576505 - Pleiotropic drug resistance in b-cell chronic lymphocytic leukaemia--the role of bcl-2 ... 6641735 - Factors involved in the sensitivity of stentor to colchicine, lumicolchicine, and vinbl... 15522265 - Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of... 8608115 - Defective ph regulation of acidic compartments in human breast cancer cells (mcf-7) is ... 16501655 - Evaluation of drug toxicity in clinical trials. 16021875 - Pharmacological resistance to antiretroviral drugs. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2011-11-22 |
Journal Detail:
|
Title: Cancer research Volume: 72 ISSN: 1538-7445 ISO Abbreviation: Cancer Res. Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-01-04 Completed Date: 2012-02-21 Revised Date: 2013-05-23 |
Medline Journal Info:
|
Nlm Unique ID: 2984705R Medline TA: Cancer Res Country: United States |
Other Details:
|
Languages: eng Pagination: 33-44 Citation Subset: IM |
Copyright Information:
|
©2011 AACR. |
Affiliation:
|
Department of Systems Medicine and Bioengineering, The Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, Texas, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
therapeutic use* Humans Neoplasms / drug therapy*, genetics Transcription, Genetic* |
| Grant Support | |
ID/Acronym/Agency:
|
U54 CA149196-01/CA/NCI NIH HHS; U54 CA149196-01S1/CA/NCI NIH HHS; U54 CA149196-02/CA/NCI NIH HHS; U54CA149196/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coa...
Next Document: Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and atte...